Sirio Pharma Co Ltd
SZSE:300791

Watchlist Manager
Sirio Pharma Co Ltd Logo
Sirio Pharma Co Ltd
SZSE:300791
Watchlist
Price: 25.7 CNY -5.31% Market Closed
Market Cap: 6B CNY
Have any thoughts about
Sirio Pharma Co Ltd?
Write Note

Income Statement

Earnings Waterfall
Sirio Pharma Co Ltd

Revenue
4B CNY
Cost of Revenue
-2.8B CNY
Gross Profit
1.2B CNY
Operating Expenses
-764.8m CNY
Operating Income
475.9m CNY
Other Expenses
-141.6m CNY
Net Income
334.3m CNY

Income Statement
Sirio Pharma Co Ltd

Rotate your device to view
Income Statement
Currency: CNY
Jun-2019 Sep-2019 Dec-2019 Mar-2020 Jun-2020 Sep-2020 Dec-2020 Mar-2021 Jun-2021 Sep-2021 Dec-2021 Mar-2022 Jun-2022 Sep-2022 Dec-2022 Mar-2023 Jun-2023 Sep-2023 Dec-2023 Mar-2024 Jun-2024
Revenue
Revenue
1 642
N/A
1 625
-1%
1 580
-3%
1 554
-2%
1 710
+10%
1 866
+9%
2 067
+11%
2 216
+7%
2 316
+5%
2 362
+2%
2 369
+0%
2 283
-4%
2 315
+1%
2 409
+4%
2 507
+4%
2 788
+11%
2 941
+5%
3 222
+10%
3 582
+11%
3 831
+7%
4 028
+5%
Gross Profit
Cost of Revenue
(1 091)
(1 082)
(1 064)
(1 046)
(1 151)
(1 259)
(1 396)
(1 499)
(1 564)
(1 601)
(1 596)
(1 583)
(1 604)
(1 680)
(1 731)
(1 947)
(2 076)
(2 261)
(2 498)
(2 675)
(2 787)
Gross Profit
551
N/A
543
-1%
516
-5%
508
-1%
560
+10%
607
+8%
671
+11%
717
+7%
752
+5%
761
+1%
773
+2%
699
-10%
711
+2%
729
+3%
777
+7%
841
+8%
864
+3%
961
+11%
1 085
+13%
1 156
+7%
1 241
+7%
Operating Income
Operating Expenses
(312)
(327)
(356)
(341)
(360)
(368)
(361)
(399)
(414)
(427)
(483)
(459)
(477)
(492)
(528)
(578)
(609)
(663)
(696)
(711)
(765)
Selling, General & Administrative
(245)
(254)
(281)
(290)
(318)
(332)
(312)
(345)
(347)
(359)
(380)
(385)
(404)
(416)
(341)
(491)
(522)
(570)
(602)
(665)
(709)
Research & Development
(67)
(66)
(62)
(62)
(66)
(68)
(62)
(71)
(74)
(74)
(77)
(84)
(82)
(85)
(70)
(84)
(88)
(95)
(97)
(119)
(131)
Depreciation & Amortization
0
0
(18)
0
0
0
(24)
0
0
0
(35)
0
0
0
(123)
0
0
0
(67)
0
0
Other Operating Expenses
0
(7)
7
12
24
32
36
18
7
6
10
10
9
8
6
(2)
1
3
71
73
75
Operating Income
239
N/A
216
-10%
160
-26%
167
+5%
200
+20%
239
+19%
310
+30%
318
+3%
338
+7%
333
-2%
291
-13%
240
-17%
234
-3%
237
+1%
249
+5%
264
+6%
255
-3%
298
+17%
389
+30%
445
+15%
476
+7%
Pre-Tax Income
Interest Income Expense
(13)
(15)
(8)
1
14
10
6
13
(3)
(4)
(1)
(5)
13
25
16
9
(18)
(46)
(107)
(116)
(124)
Non-Reccuring Items
0
0
(1)
0
0
0
(1)
0
0
(1)
(2)
0
0
1
(6)
0
0
0
0
0
0
Total Other Income
4
4
6
7
(2)
(2)
(2)
(8)
(2)
(8)
(7)
(7)
(12)
(9)
(8)
(14)
(8)
(7)
(9)
(12)
(13)
Pre-Tax Income
230
N/A
205
-11%
157
-24%
175
+12%
212
+21%
247
+17%
312
+26%
323
+4%
334
+3%
320
-4%
281
-12%
229
-19%
234
+2%
254
+8%
252
-1%
259
+3%
229
-11%
246
+7%
273
+11%
318
+16%
339
+7%
Net Income
Tax Provision
(20)
(19)
(14)
(19)
(34)
(38)
(55)
(59)
(55)
(49)
(49)
(40)
(38)
(46)
(39)
(42)
(47)
(50)
(33)
(42)
(42)
Income from Continuing Operations
210
187
143
156
178
209
257
265
279
272
232
189
196
208
212
216
182
196
240
275
296
Income to Minority Interest
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
11
21
25
41
39
38
Net Income (Common)
210
N/A
187
-11%
143
-24%
156
+9%
178
+14%
209
+17%
257
+23%
265
+3%
279
+5%
272
-3%
232
-15%
189
-18%
196
+4%
208
+6%
212
+2%
227
+7%
204
-10%
221
+9%
281
+27%
315
+12%
334
+6%
EPS (Diluted)
1.55
N/A
1.38
-11%
0.97
-30%
0.86
-11%
0.99
+15%
1.16
+17%
1.43
+23%
1.47
+3%
1.55
+5%
1.51
-3%
0.94
-38%
1.02
+9%
1.03
+1%
1.13
+10%
0.9
-20%
1.25
+39%
1.12
-10%
1.23
+10%
1.2
-2%
1.34
+12%
1.4
+4%

See Also

Discover More